Therapeutic progression of quinazolines as targeted chemotherapeutic agents

被引：92

作者：

Bansal, Ranju ^{[1
]}

Malhotra, Anjleena ^{[1
]}

机构：

[1] Panjab Univ, Univ Inst Pharmaceut Sci, Sect 14, Chandigarh 160014, India

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2021年 / 211卷

关键词：

Quinazoline; Targeted therapy; Anticancer agents; Protein kinase inhibitors; SAR; BCRP inhibitors; TYROSINE KINASE INHIBITORS; POTENT EGFR INHIBITORS; CYCLIN-DEPENDENT KINASE; AURORA-B KINASE; BIOLOGICAL EVALUATION; IN-VITRO; 4-ANILINOQUINAZOLINE DERIVATIVES; LUNG-CANCER; QUINAZOLINE-2,4(1H,3H)-DIONE DERIVATIVES; PHOSPHATIDYLINOSITOL; 3-KINASE;

D O I：

10.1016/j.ejmech.2020.113016

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Presently cancer is a grave health issue with predominance beyond restrictions. It can affect any organ of the body. Most of the available chemotherapeutic drugs are highly toxic, not much selective and eventually lead to the development of resistance. Therefore, a target specific palliative approach for the treatment of cancer is required. Remarkable advancements in science have illuminated various molecular pathways responsible for cancer. This has resulted in abundant opportunities to develop targeted anticancer agents. Quinazoline nucleus is a privileged scaffold with significant diversified pharmacological activities. Numerous established anticancer quinazoline derivatives constitute a new class of chemotherapeutic agents which are found to act by inhibiting various protein kinases as well as other molecular targets. A recent update on various quinazoline derivatives acting on different types of molecular targets for the treatment of cancer has been compiled in this review. Brief SAR studies of quinazoline derivatives acting through different mechanisms of action have been highlighted. The comprehensive medicinal chemistry aspects of these agents in this review provide a panoramic view to the biologists as well as medicinal chemists working in this area and would assist them in their efforts to design and synthesize novel quinazoline based anticancer compounds. (C) 2020 Elsevier Masson SAS. All rights reserved.

引用

页数：30

共 189 条

[91] The combination of 4-anilinoquinazoline and cinnamic acid: A novel mode of binding to the epidermal growth factor receptor tyrosine kinase [J].

Li, Dong-Dong ;

Lv, Peng-Cheng ;

Zhang, Hui ;

Zhang, Hong-Jia ;

Hou, Ya-Ping ;

Liu, Kai ;

Ye, Yong-Hao ;

Zhu, Hai-Liang .

BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (16) :5012-5022

[92] Design and synthesis of 4,6-substituted-(diaphenylamino)quinazolines as potent EGFR inhibitors with antitumor activity [J].

Li, Huan-Qiu ;

Li, Dong-Dong ;

Lu, Xiang ;

Xu, Yun-Yun ;

Zhu, Hai-Liang .

BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (01) :317-323

[93] Discovery of novel quinazolines as potential anti-tubulin agents occupying three zones of colchicine domain [J].

Li, Wenlong ;

Yin, Ying ;

Shuai, Wen ;

Xu, Feijie ;

Yao, Hong ;

Liu, Jie ;

Cheng, Keguang ;

Xu, Jinyi ;

Zhu, Zheying ;

Xu, Shengtao .

BIOORGANIC CHEMISTRY, 2019, 83 :380-390

[94] The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton [J].

Li, Yang ;

Xiao, Jie ;

Zhang, Qizhi ;

Yu, Wenmei ;

Liu, Mengqin ;

Guo, Yu ;

He, Jun ;

Liu, Yunmei .

BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (03) :568-577

[95] Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors [J].

Liu, Lee Tai ;

Yuan, Ta-Tung ;

Liu, Hung-Huang ;

Chen, Shyh-Fong ;

Wu, Ying-Ta .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (22) :6373-6377

[96] Structure-based drug design: Synthesis and biological evaluation of quinazolin-4-amine derivatives as selective Aurora A kinase inhibitors [J].

Long, Liang ;

Wang, Yong-Heng ;

Zhuo, Jun-Xiao ;

Tu, Zheng-Chao ;

Wu, Ruibo ;

Yan, Min ;

Liu, Quentin ;

Lu, Gui .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 157 :1361-1375

[97] Synthesis, characterization, screening and docking analysis of 4-anilinoquinazoline derivatives as tyrosine kinase inhibitors [J].

Lu, Shuang ;

Zheng, Wei ;

Ji, Liyun ;

Luo, Qun ;

Hao, Xiang ;

Li, Xianchan ;

Wang, Fuyi .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2013, 61 :84-94

[98] Mammalian cyclin-dependent kinases [J].

Malumbres, M ;

Barbacid, M .

TRENDS IN BIOCHEMICAL SCIENCES, 2005, 30 (11) :630-641

[99] Advances in the structural biology, VEGF-R kinase inhibitors for design and clinical development of the treatment of angiogenesis [J].

Manley, PW ;

Bold, G ;

Brüggen, J ;

Fendrich, G ;

Furet, P ;

Mestan, J ;

Schnell, C ;

Stolz, B ;

Meyer, T ;

Meyhack, B ;

Stark, W ;

Strauss, A ;

Wood, J .

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2004, 1697 (1-2) :17-27

[100] Idelalisib: First Global Approval [J].

Markham, Anthony .

DRUGS, 2014, 74 (14) :1701-1707

← 5 6 7 8 9 10 11 12 13 14 →